4SC AG (FRA: VSC)

Market Cap	42.22M
Revenue (ttm)	359.00K
Net Income (ttm)	-7.53M
Shares Out	10.91M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190
Open	4.110
Previous Close	3.860
Day's Range	3.610 - 4.110
52-Week Range	3.610 - 11.200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About 4SC AG

4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 13
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VSC

Financial Performance

In 2023, 4SC AG's revenue was 304,000, a decrease of -30.28% compared to the previous year's 436,000. Losses were -8.24 million, -42.64% less than in 2022.